AbbVie Downplays Impact Of Viekira Pak Safety Issues
This article was originally published in Scrip
Executive Summary
AbbVie Inc. continued to downplay the potential impact of a labeling change for its hepatitis C combination drug Viekira Pak, saying during its third quarter earnings call on Oct. 30 that the safety-driven update affects a small percentage of patients and won't prove material to the product's sales.